Using C-reactive protein to albumin ratio to predict heart events in acute coronary syndrome
Prediction of Acute Coronary Syndrome In-hospital Major Adverse Cardiovascular Events by High Sensitivity C- Reactive Protein to Albumin Ratio
This study is testing if a blood test measuring the C-reactive protein to albumin ratio can help predict serious heart problems in patients with acute coronary syndrome while they are in the hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06673381 on ClinicalTrials.gov |
What this trial studies
This observational study assesses the predictive value of the high sensitive C-reactive protein to albumin ratio (hs-CAR) for in-hospital short-term major adverse cardiac events (MACEs) in patients with acute coronary syndrome (ACS). Conducted at the coronary care unit of Sohag University Hospital, the study includes patients diagnosed with ACS based on established guidelines. Blood samples are collected upon admission to measure hs-CRP and serum albumin levels, allowing for the calculation of hs-CAR and classification of patients into high and low hs-CAR groups. The primary endpoint is the occurrence of in-hospital MACEs, which include serious cardiac complications.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with acute coronary syndrome who are not candidates for primary percutaneous coronary intervention.
Not a fit: Patients under 18, those with severe chronic conditions, or recent infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the prediction of serious cardiac events in ACS patients, potentially leading to better management and outcomes.
How similar studies have performed: While the specific approach of using hs-CAR in this context may be novel, similar studies have explored biomarkers for predicting cardiac events with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients aged 18 Year or older presented by ACS not candidet for primary percutaneus coronary intervention ( PCI ) . Exclusion Criteria: * • Patients aged \< 18 years old * Patients who have eGFR \<60 ml/kg /m2 * Patients who have malignancies * Patients who have chronic heart failure (NYHA class \>II) * Pateints who have chronic liver disease * Patients who have nephrotic syndrome * Patients who have acute cerebrovascular stroke * Pregnant women * Patients who have recent infection
Where this trial is running
Sohag
- Sohag faculty of medicine — Sohag, Egypt (Recruiting)
Study contacts
- Principal investigator: Amira Elbasuony, resident — Sohag University
- Study coordinator: Amira Elbasuony, resident
- Email: amiraelbadawy518@gmail.com
- Phone: 01113695925
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.